BioMarin Pharmaceutical Inc.
Gregory R Friberg (EVP, Chief R&D Officer) sells BMRN shares
About this filing
BioMarin Pharmaceutical Inc. (BMRN) filed Form 4 (insider transaction) with the SEC on Nov 19, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Gregory R Friberg · EVP, Chief R&D Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | S · open-market saleFootnotes F1 | −5,147 | $58.81 | $302,710.51 | 42,585 | Direct |
Footnotes
- F1 The price in column 4 is the weighted average price. The purchase price actually received ranged from $58.77 to $58.855. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
More BMRN filings
- SC 13G
Filed Nov 20, 2026
- 144
Filed Nov 18, 2026
- 10-Q
Filed Nov 3, 2026
- 8-K
Filed Nov 2, 2026
- 8-K
Filed Oct 6, 2026
- 4
Filed Oct 1, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.